Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged ≥ 18 years.
Clinical diagnosis of nonsegmental vitiligo and meet the following:
* T-BSA ≥ 5%
* T-VASI score ≥ 4
* F-BSA ≥ 0.5%
* F-VASI score ≥ 0.5
Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
Willingness to avoid pregnancy or fathering children.
You may not be if
Other forms of vitiligo or skin depigmentation disorders.
Clinically significant abnormal TSH or free T4 at screening.
Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1.
Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®.
History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo.
Spontaneous and significant repigmentation within 6 months prior to screening.
Women who are pregnant, considering pregnancy, or breast feeding.
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
Evidence of infection with TB, HBV, HCV or HIV.
History of failure to JAK inhibitor treatment of any inflammatory disease.
Laboratory values outside of the protocol-defined ranges.
